What is the 13F Pro Quality Score for NPCE?

13F Pro ranks NeuroPace Inc (NPCE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NPCE's current score at https://13fpro.ai/research/NPCE (free sign-up required for the full ranking).

Where does 13F Pro source NPCE data?

All NeuroPace Inc fundamentals and ownership data come directly from SEC EDGAR. NeuroPace Inc files with the SEC under CIK 1528287. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NPCE in?

NeuroPace Inc (NPCE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NPCE research updated on 13F Pro?

NPCE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NeuroPace Inc(NPCE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1528287 NPCE stock profile & AI dashboard →

13F Pro Quality Score

30.5/100

Rank #2,353 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

81.3/100

Profitability

16.1/100

Balance Sheet

9.9/100

Earnings Quality

30.0/100

Free Cash Flow

14.7/100

Institutional Flow

49.2/100

Revenue Scale

17.1/100

Dilution Risk

15.8/100

NPCE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NeuroPace Inc (NPCE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NPCE at 30.5/100 on a 32-signal composite quality model, placing it at rank #2,353 of 2,879 stocks — the bottom half of the AI-ranked universe. NPCE scores in the top quartile across revenue growth (81.3). Areas of concern include balance sheet strength (9.9) and free cash flow (14.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), NeuroPace Inc reports quarterly revenue of $22.1M, net income of $-6.7M, free cash flow of $-6.0M. Top institutional holders of NPCE by reported 13-F value include Polar Capital Holdings Plc, Soleus Capital Management, L.P., MORGAN STANLEY, based on the most recent SEC filings. NPCE trades on the Nasdaq exchange and files with the SEC under CIK 1528287. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NPCE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NeuroPace Inc directly from SEC EDGAR. NeuroPace Inc's 13F Pro composite quality score has ranged between 8 and 58 since 2022, currently 30.5 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about NeuroPace Inc

Quirks, history, and lore behind NPCE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the range of tens of millions of dollars — this is not a blockbuster yet — with a focus on growing its implanted patient base rather than near-term profit.
3
The History
Founded in the late 1990s, it spent years navigating FDA approval before finally bringing its flagship device to market — a journey measured in decades, not quarters.
4
The Secret
Its device lives inside the skull, continuously monitoring brain activity and delivering on-demand electrical stimulation only when it detects a seizure coming — essentially a pacemaker for the brain.
5
The Lore
The company targets drug-resistant epilepsy patients who have failed multiple medications — a population of millions with very few options left and nowhere else to turn.
6
The Giveaway
Its RNS System — the only closed-loop responsive neurostimulation device approved by the FDA for epilepsy — is literally a tiny computer bolted to your brain that fires electricity when it senses trouble.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$22.1M

Net Income

Q1 2026

$-6.7M

Free Cash Flow

Q1 2026

$-6.0M

D/E Ratio

Q1 2026

4.08

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+25.1% YoY

$100.0MFY 2025

FY21 $45.2MFY22 $45.5MFY24 $79.9MFY25 $100.0M

Net Income

+20.9% YoY

$-21.5MFY 2025

FY21 $-36.1MFY22 $-47.1MFY24 $-27.1MFY25 $-21.5M

Operating Income

+24.6% YoY

$-16.3MFY 2025

FY21 $-23.7MFY22 $-40.8MFY24 $-21.7MFY25 $-16.3M

EPS (Diluted)

+29.0% YoY

$-0.66FY 2025

FY21 $-2.17FY22 $-1.91FY24 $-0.93FY25 $-0.66

Total Assets

+11.5% YoY

$105.6MFY 2025

FY21 $133.6MFY22 $114.1MFY24 $94.6MFY25 $105.6M

Total Debt

-1.1% YoY

$58.9MFY 2025

FY21 $49.8MFY22 $52.9MFY24 $59.5MFY25 $58.9M

Op. Cash Flow

+38.7% YoY

$-11.0MFY 2025

FY21 $-24.6MFY22 $-36.9MFY24 $-17.9MFY25 $-11.0M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$100.0M +25.1%	$79.9M +75.5%	$45.5M +0.7%	$45.2M +9.8%	$41.1M	—
Net Income	$-21.5M +20.9%	$-27.1M +42.4%	$-47.1M -30.5%	$-36.1M -48.6%	$-24.3M	—
Operating Income	$-16.3M +24.6%	$-21.7M +46.9%	$-40.8M -71.9%	$-23.7M -81.9%	$-13.1M	—
EPS (Diluted)	$-0.66 +29.0%	$-0.93 +51.3%	$-1.91 +12.0%	$-2.17 +98.2%	$-117.85	—
Total Assets	$105.6M +11.5%	$94.6M -17.1%	$114.1M -14.6%	$133.6M +138.7%	$56.0M	—
Total Debt	$58.9M -1.1%	$59.5M +12.5%	$52.9M +6.2%	$49.8M -5.7%	$52.9M	—
Operating Cash Flow	$-11.0M +38.7%	$-17.9M +51.3%	$-36.9M -50.0%	$-24.6M -13.7%	$-21.6M	—

AI Insight: NPCE Financial Trends

Revenue growth stalled in Q1 2026 after reaching $27M peak, while operating cash flow turned negative again despite late-2025 improvement.

• Revenue grew from $19M (Q2 2024) to $27M (Q3–Q4 2025), a 42% increase over 18 months, then declined to $22M in Q1 2026.

• Operating margin improved from -32% (Q2 2024) to -7% (Q4 2025), but deteriorated to -27% in Q1 2026.

• Operating cash flow moved positive $1M in Q4 2025, first positive quarter, but reverted to -$6M in Q1 2026.

⚠ Equity halved from $24M (Q1 2025) to $14M (Q1 2026); persistent net losses eroding book value.

⚠ Q1 2026 revenue decline and negative cash flow suggest seasonality or demand weakness after late-2025 plateau.

AI Insight: NPCE Ratio Trends

Profitability collapsed in Q1 2026 after three quarters of steady margin improvement, signaling a sharp operational or seasonal reversal.

• Operating margin deteriorated to -25.2% in Q1 2026 from -6.7% in Q4 2025, unwinding nine months of gains from -32.4% baseline.

• ROIC swung to -30.3% in Q1 2026 versus -9.1% in Q4 2025, largest quarterly decline in the dataset, destroying shareholder value.

• Debt-to-equity rose to 4.08x in Q1 2026 from 3.09x in Q4 2025, reversing deleveraging trend and increasing financial risk.

⚠ Q1 2026 reversal is severe and unexplained by data alone; verify if seasonal, one-off charge, or structural deterioration.

⚠ Company remains deeply unprofitable across all metrics; path to positive returns unclear and capital efficiency remains negative.

Get alerted when NPCE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NeuroPace Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NPCE

Polar Capital Holdings Plc
$43.4M3,298,104 sh
Soleus Capital Management, L.P.
$38.6M2,932,207 sh
MORGAN STANLEY
$33.8M2,566,839 sh
First Light Asset Management, LLC
$32.3M2,459,966 sh
BlackRock, Inc.
$30.9M2,346,333 sh
ORBIMED ADVISORS LLC
$27.6M2,096,527 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$19.1M1,451,611 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.8M1,123,711 sh
DEUTSCHE BANK AG\
$12.3M932,090 sh
ARMISTICE CAPITAL, LLC
$9.1M692,000 sh

Fund	Value	Shares
Polar Capital Holdings Plc	$43.4M	3,298,104
Soleus Capital Management, L.P.	$38.6M	2,932,207
MORGAN STANLEY	$33.8M	2,566,839
First Light Asset Management, LLC	$32.3M	2,459,966
BlackRock, Inc.	$30.9M	2,346,333
ORBIMED ADVISORS LLC	$27.6M	2,096,527
DRIEHAUS CAPITAL MANAGEMENT LLC	$19.1M	1,451,611
VANGUARD CAPITAL MANAGEMENT LLC	$14.8M	1,123,711
DEUTSCHE BANK AG\	$12.3M	932,090
ARMISTICE CAPITAL, LLC	$9.1M	692,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NPCE on your watchlist

Track score changes the day NeuroPace Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NPCE a good stock to buy?

13F Pro's AI-powered analysis of NeuroPace Inc (NPCE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NPCE are available on the NPCE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NPCE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NPCE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NeuroPace Inc's investment landscape.